Sari la conținut

ADAPTIVE BIOTECHNOLOGIES CORP: Diferență între versiuni

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
(Pagină nouă: Pagina dedicata companiei ADAPTIVE BIOTECHNOLOGIES CORP listata cu simbolul US.ADPT ==Descriere companie== Adaptive Biotechnologies Corporation (https://www.adaptivebiotech.com/) is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adap...)
 
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).)
 
Linia 2: Linia 2:


==Descriere companie==
==Descriere companie==
Adaptive Biotechnologies Corporation (https://www.adaptivebiotech.com/) is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). It uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. It also focuses on developing immune-mediated therapies in oncology and other disease areas.
Adaptive Biotechnologies Corporation (https://www.adaptivebiotech.com/) is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic [[test]] detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). It uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. It also focuses on developing immune-mediated therapies in oncology and other disease areas.


==Grafic actiuni companie==
==Grafic actiuni companie==
Utilizator anonim